Patheon to Invest $45 Million, Expanding Capabilities to Support Continued Growth
June 29 2017 - 12:00PM
Business Wire
Investments in key service areas to meet
growing customer demand
Patheon N.V. (NYSE: PTHN), a leading global provider of
high-quality drug development and delivery solutions to the
pharmaceutical sector, today announced that it expects to invest
approximately $45 million at key sites across its global network to
meet growing customer demand for expanded service capabilities.
“As outsourcing of Pharma development and manufacturing services
continues to grow, our customers will need even more advanced
technologies and customized solutions to meet their business
needs,” said Michel Lagarde, president of Patheon. “With the
increasing marketplace pressures, pharma companies are looking to
build more reliable, flexible and cost-efficient supply chains.
With our focus on people, process and capabilities, Patheon is
uniquely positioned to partner with pharma companies to achieve
their objectives – cost effectively while delivering the highest
quality.”
Patheon is investing in the following key areas:
Commercial & Development Spray DryingThe company’s
recently acquired site located in Florence, South Carolina, will be
adding commercial spray drying capabilities, complementing the
existing development capabilities available at the company’s
low-solubility center of excellence in Bend, Oregon. The
15,000-sq.-ft. dedicated suite will contain two spray dryers
delivering development and commercial scale spray-dried dispersion
(SDD) services. The suite is expected to be online in 2019. Spray
Drying is a process that creates amorphous solid dispersions and is
a key technology utilized to enhance the solubility of poorly
soluble drugs.
At the Bend, Oregon site the company plans to expand existing
development SDD capabilities with a new cGMP analytical lab,
manufacturing suite and additional development scale spray drying.
Together, the expertise and capabilities at the Florence and Bend
locations provide clients with an end-to-end solution for products
with solubility challenges, from development to commercialization,
to successfully bring products to market.
Flexible Manufacturing SolutionsPatheon has invested in a
new commercial sterile product manufacturing facility in its Monza,
Italy site. The facility will house three, 40 sq M lyophilizers
with associated eight-headed integrated filling equipment for both
lyo and liquid formulations for small and large molecules in a
range of vial specifications. The equipment will have full CIP/SIP
systems, auto loading for the lyophilizers contained in full RABs
systems to ensure the highest level of sterility assurance.
Patheon also plans to expand its sterile product Pharmaceutical
Development Services (PDS) at the Monza facility. The sterile suite
will contain two 7m2 lyophilizers and associated sterile vial
filling line and analytical laboratory. This new facility will
serve the company’s clients seeking to develop both small and large
molecule injectable products (liquid and lyo formulations) and will
be operational in mid-2019. All of Patheon’s PDS sterile suites are
co-located within facilities with commercial scale capabilities to
ease with the transition from clinical to commercialization.
Patheon will also expand its packaging and serialization
capabilities at its Greenville, NC site. The company has built a
new filling and packaging suite and upgraded another of its
packaging lines with new technology to improve efficiency and
reduce change-over time. The newly constructed 4,800-square-foot
suite will come online this fall and features a filling and
packaging line equipped with an Optel serialization system. The
state-of-the-art system includes cameras, pharma proof stations,
line master, and bottle and bundle tracker equipment.
These investments will help clients realize greater efficiency
and accelerate the delivery of products to market.
About PatheonPatheon is a leading global provider of
pharmaceutical development and manufacturing services. With
approximately 9,100 employees and contractors worldwide, Patheon
provides a comprehensive, integrated and highly customizable set of
solutions to help clients of all sizes satisfy complex development
and manufacturing needs at any stage of the pharmaceutical
development cycle. A Healthier World. Delivered.
www.patheon.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170629005753/en/
PatheonMari Mansfield, 919-226-3137Senior Director, External
CommunicationsMari.Mansfield@Patheon.commedia@patheon.com
PATHEON N.V. (NYSE:PTHN)
Historical Stock Chart
From Oct 2024 to Nov 2024
PATHEON N.V. (NYSE:PTHN)
Historical Stock Chart
From Nov 2023 to Nov 2024
